• Eugene R Viscusi.
• a Thomas Jefferson University, Acute Pain Management, Department of Anesthesiology , US 111 S. 11th Street, Suite G8490, Philadelphia, PA 19107, USA +1 21 59 55 61 61 ; +1 21 59 23 55 07 ; eugene.viscusi@jefferson.edu.
• Expert Opin Drug Saf. 2015 Jan 1; 14 (12): 1801-3.

AbstractThe need for better post-surgical pain management continues to be unmet, despite clinicians' awareness and concern for many years. Opioids remain the standard of care because of their analgesic efficacy; however, opioid use is often associated with adverse effects and poor patient outcomes. Multimodal analgesic regimens have recently been endorsed as a way to provide adequate post-surgical pain control while reducing opioid consumption. Liposome bupivacaine is a liposomal formulation of bupivacaine indicated for a single administration into the surgical site. Based on the available clinical trial data compiled to date, as well as the author's review of publicly available post-marketing safety information, liposome bupivacaine may be a viable addition to currently available therapeutic options for post-surgical analgesia while reducing potential risks associated with use of opioid analgesics, and may represent a useful addition to the multimodal analgesic modalities currently used for post-operative pain management. The potential for its use in other areas is also being investigated. The purpose of this review is to examine the currently available post-marketing safety information on liposome bupivacaine.

21 keywords...

hide…